ClinicalTrials.gg
Status unknownNCT03661749Updated Sep 7, 2018

Urinary Protein to Creatinine Ratio in Term Pregnant Women

An interventional study of clean catch in Pregnancy Complications, sponsored by St. Luke's Hospital, Pennsylvania. Status unknown at 1 site in United States. Open to female participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-09-07.

Sponsored by St. Luke's Hospital, Pennsylvania · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Sep 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
16 Years to 55 Years
Sex
Female
01

Study summary

This study will determine the incidence of elevated U Pr/Cr in normal term pregnant women. In addition we will determine if a "clean catch" urine has an effect on the U Pr/Cr.

Read the detailed description

Clean catch urine should be used due to possible vaginal secretion contamination with falsely elevated U Pr/Cr ratio. However, no supporting reference was found in the article and no control group with random urine collection for comparison to clean catch specimen U Pr/Cr was included in their study. The original studies that validated spot Pr/Cr urine as a predictor of 24 -hour total urine protein used random non-clean catch random urines . They had an r value of .93-.99 in estimating total protein excreted in 24 hours. At our institution we use Siemens-base test to determine U Pr/Cr. In the product insert the company states that no special patient preparation is necessary.

Thus, this study will determine the incidence of elevated U Pr/Cr in normal term pregnant women. In addition we will determine if a "clean catch" urine has an effect on the U Pr/Cr.

02

Conditions studied

  • Pregnancy Complications
03

In context

Pregnancy Complications

445 studies on the registry are indexed under Pregnancy Complications; 115 are open to participants now.

This study's planned enrollment of 240 is above the median of 147 across 224 interventional studies indexed under Pregnancy Complications.

Browse Pregnancy Complications studies →

Lead sponsor

St. Luke's Hospital, Pennsylvania is the lead sponsor of 18 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women of 37 weeks gestation or greater

Exclusion criteria

Exclusion Criteria:

  • Urinary tract infections
  • Hypertension
  • Pre-eclampsia
  • Renal dysfunction
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Clean catch

    women in this group will collect urine for PR/CR using a clean catch technique

    Other: clean catch

  • Placebo comparator
    Non-clean catch

    women in this group will not employ clean catch technique

    Other: clean catch

Interventions

  • Otherclean catch

    clean catch technique applied to collect urine for PR/CR ratio

06

What researchers measure

Primary outcomes

  1. elevated PR/CR ratio using clean catch technique

    this will be the proportion of patients with PR/CR ratio greater than or equal to 0.3 in urine using a clean catch method.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Report the incident of PR/CR ratio greater than 0.3

    overall incident of elevated PR/CR ratio in healthy term pregnant women

    Time frame: through study completion, average of 1 year

07

Study locations

1 site
  • St Luke's University Hospital
    Bethlehem, Pennsylvania 18015, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2018; primary completion for Aug 2019, 11 months later.

Of 133 non-industry interventional studies with no phase under Pregnancy Complications, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 11 months is below that.

Counting every sponsor, half of 133 studies reached it within 29 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2018
First posted
Sep 7, 2018
StartEst.
Sep 2018
Primary completionEst.
Aug 2019
CompletionEst.
Nov 2019
Last update
Sep 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03661749
Lead sponsor
St. Luke's Hospital, Pennsylvania
Responsible party
James Anasti, MD (Clinical Professor of OB/GYN, St. Luke's Hospital, Pennsylvania) — Principal investigator
First posted
Sep 7, 2018
Start date
Sep 2018 (estimated)
Primary completion
Aug 2019 (estimated)
Completion
Nov 2019 (estimated)
Last update
Sep 7, 2018

Study contacts

James N Anasti, MD
Contact
anastij@slhn.org
484-526-8878
James N Anasti, MD
principal investigator · St Luke's University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion